Assuming the COMPASS results are enough to convince regulators to make the low dose of rivaroxaban used in the study available to clinicians, the trial should influence how patients with stable ...
MENLO PARK, Calif., Feb. 27, 2025 /PRNewswire/ -- MyOme, Inc., a leading clinical whole genome testing and polygenic risk modelling (PRS) company, is proud to announce the launch of its coronary ...
Introduction: The positive outcomes of the COMPASS trial raise questions about the proportion of patients who could benefit from additional therapy with rivaroxaban in real-world practice. Objectives: ...
Dezeen shares the project of design student Ken Nakagaki, who has adapted a device to work with computer aided design (CAD) software to replicate digital files on paper. The device, named Comp*pass, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results